• A second-generation androgen receptor blocker added to other prostate cancer treatments improves five-year survival rates for people with metastasized disease.
• The blocker, enzalutamide, improved outcomes in a range of prostate cancers even where chemotherapy is ineffective.
• Enzalutamide works by reducing the ability of prostate cancer cells to bind to testosterone, which promotes cancer growth.

By Robby Berman on April 4, 2023 — Fact checked by Hannah Flynn

read full article